Business Wire

Fishawack continues to build best-in-class service offering with Dudnyk acquisition

Share

Fishawack, a leading independent healthcare communications specialist, is excited to announce its acquisition of Dudnyk, the Philadelphia-based healthcare communications agency. Dudnyk is an award-winning, full-service agency that specializes in creating insight-driven, authentic brand experiences that unite specialty physicians and their patients. They leverage strategic, scientific, and creative capabilities to serve clients in the biotech, pharmaceutical, and medical device industries.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190320005204/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Dudnyk leadership team includes Christopher Tobias, PhD, President; Laurie Bartolomeo, EVP, Creative Director; Drew Desjardins, EVP, Chief Strategy Officer; Annemarie Armstrong, EVP, Director of Client Services; John Kemble, EVP, Creative Producer. (Photo: Business Wire)

Fishawack’s goal is to increase the range of healthcare communications services that it can offer to commercial and medical affairs teams. It now has healthcare creative agencies that span East to West Coast USA and Europe.

“Dudnyk brings to Fishawack a particular expertise in rare diseases, oncology, and launching breakthrough molecular medicines,” explains Christopher Tobias, President of Dudnyk. “Our seasoned team will complement Fishawack’s already expansive offering, especially in the area of commercial strategy and creative expertise.”

“Fishawack has wanted to add an East Coast healthcare marketing agency of scale and is pleased to have found that partnership with Dudnyk,” explains Oliver Dennis, CEO of Fishawack Group of Companies. “The leadership at Dudnyk clearly cares about their people, their clients, and the rare disease and oncology patients they serve. The organization’s values are very much aligned with ours.”

Fishawack is a significant provider of healthcare communication services to both medical affairs and marketing teams. Its history of acquisitions is based on the belief that the teams are stronger together than individually. “It’s not just about acquiring,” said Gail Flockhart, Group President, “it’s about making the synergies real, which means connecting talent across the organization. The best part of every acquisition is discovering what we can learn from each other.”

“Fishawack is unlike traditional networks that make introductions as client needs arise; instead, we form high-performing, inter-company business relationships early on,” says Oliver Dennis. “This is important to our clients who depend on continuity of relationships and teams they can depend on. We’re currently undergoing a rebranding of Fishawack that reflects these core beliefs, and we’re looking forward to sharing this with the healthcare marketing community in the near future.”

Fishawack received corporate finance and legal support from Rick Stark and Phil Hall of KPMG and George Danczak and James Finney of Addleshaw Goddard LLP (UK), respectively. Their financial sponsor is LDC.

For more information about the Fishawack Group, please contact Gail Flockhart, Group President, at  gail.flockhart@fishawack.com . For more information about Dudnyk, please contact Christopher Tobias, PhD, President, at ctobias@dudnyk.com .

About the Fishawack Group

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in the UK (Knutsford, Oxford, London, and Brighton), the USA (Philadelphia, PA, and San Diego, CA), Switzerland (Basel), and India (Hyderabad).

Fishawack comprises two international divisions, Fishawack Medical Communications, developing and delivering services in the fields of medical communications, scientific engagement, publications, market access, strategic consultancy, and thought leader consultancy, and Fishawack Creative, offering strategic planning, creative development, advertising and promotion, and tactical execution.

We have built our reputation on excellence, creativity, and transparency.

About Dudnyk

Independently owned for the past 25 years, Dudnyk is an award-winning, full-service healthcare advertising agency that specializes in creating insight-driven, authentic brand experiences that unite specialty physicians and their patients. They leverage strategic, scientific, and highly creative capabilities to serve clients in the biotech, pharmaceutical, and medical device industries. Dudnyk offers a unique culture, fosters individual career growth, and promotes collaboration among all disciplines. Learn more at dudnyk.com or @DudnykHealth.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Fishawack Group
Gail Flockhart, Group President
gail.flockhart@fishawack.com
or
Dudnyk
Christopher Tobias, PhD, President
ctobias@dudnyk.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 18:22:00 EEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/ Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 15:30:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 15:00:00 EEST | Press release

The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye